Variants of chymosin with improved milk clotting properties.

Variants of chymosin with improved milk-clotting properties are disclosed.

Provided herein are compositions and methods for producing milk proteins, which allow for safe, sustainable and humane production of milk proteins for commercial use, such as use in food compositions. The disclosure further teaches methods of increasing the production/accumulation of casein proteins in host cells by co-expressing a kinase capable of phosphorylating the casein protein. Specifically, the disclosure provides host cells comprising a heterologous casein protein and a heterologous casein. Stable transgenic plants expressing heterologous caseins and heterologous kinase proteins are also provided. In some embodiments, the heterologous casein proteins of the disclosure are contained within fusion proteins comprising at least first protein and a second protein, wherein at least one of the first protein and the second protein is a milk protein, or fragment thereof. The disclosure also provides methods for producing the recombinant fusions proteins, and food compositions comprising the same.

A variant polypeptide having chymosin activity, wherein the variant has an amino acid sequence which, when aligned with the chymosin comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 2, 22, 40, 48, 50, 51, 53, 61, 62, 76, 88, 98, 99, 109, 112, 117, 125, 126, 135, 144, 160, 161, 163, 187, 189, 194, 200, 201, 202, 203, 221, 223, 240, 242, 244, 254, 267, 271, 273, 278, 280, 284, 289, 292, 294 or 295 said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered properties as compared with a reference polypeptide having chymosin activity. Such a variant polypeptide may be used in the preparation of a cheese.

The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of arteriovenous fistula nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease.

A liquid or dried granulated milk clotting aspartic protease enzyme composition and process for isolating a milk clotting aspartic protease enzyme of interest.

Variants of chymosin with improved milk clotting properties.

Variants of chymosin with improved milk-clotting properties are disclosed.

Provided herein are compositions and methods for producing milk proteins, which allow for safe, sustainable and humane production of milk proteins for commercial use, such as use in food compositions. The disclosure provides recombinant fusion proteins comprising at least first protein and a second protein, wherein at least one of the first protein and the second protein is a milk protein, or fragment thereof: The disclosure also provides methods for producing the recombinant fusions proteins, and food compositions comprising the same.

Variants of chymosin with improved properties.